Perimenopause Weight Loss: A Guide to HRT and GLP-1 Medications 

Weight gain during perimenopause affects many women in their 40s and early 50s, with research showing  an average gain of 1.1 pounds per year due to aging during this period of life. For some women, this weight accumulation can occur despite maintaining the same diet and exercise routines that previously kept their weight stable. 

This isn’t a matter of discipline or effort. The hormone changes associated with the menopause transition can fundamentally alter how your body processes and stores fat at a cellular level. Declining estrogen levels can trigger a cascade of metabolic changes that make traditional weight loss approaches not work as well as they did before. Understanding these hormonal shifts can be the first step toward effective treatment during this transition. 

Emerging clinical research reveals a promising approach: combining hormone replacement therapy with GLP-1 weight loss medications may help some postmenopausal women achieve greater weight loss than GLP-1 medication alone. While more research is needed, preliminary studies suggest this combination approach may address multiple factors contributing to midlife weight changes.

Why Traditional Weight Loss Stops Working in Perimenopause

Perimenopause begins a metabolic cascade that makes weight management exponentially harder. As your ovaries produce less estrogen, your body experiences multiple simultaneous changes that may undermine even the most disciplined efforts. 

Insulin resistance increases. Declining estrogen levels directly impair your cells’ ability to respond to insulin, causing blood sugar instability and increased fat storage. This metabolic shift happens even if your diet and exercise haven’t changed. You could be eating the exact same meals and moving just as much yet gaining weight because your cellular metabolism has fundamentally shifted. 

Muscle mass decreases. Testosterone levels drop alongside estrogen, accelerating muscle loss. Since muscle tissue burns more calories at rest than fat, losing muscle slows your metabolic rate by 2-4% per decade after age 40. This means you need fewer calories to maintain your weight with each passing year. What sustained your weight at 35 may lead to weight gain at 45.

Visceral fat accumulates. Your body redistributes fat from subcutaneous areas to visceral deposits around your abdomen. Deep belly fat isn’t just something we notice on the surface. It also plays an active role inside the body. Visceral fat, the fat stored deep around your organs, releases chemicals that cause inflammation. This inflammation makes it harder for your body to use insulin properly, which in turn leads to even more fat and inflammation, creating a difficult cycle to break. 

Appetite regulation fails. Hormonal fluctuations disrupt leptin and ghrelin, the hormones controlling hunger and satiety. Many women report increased cravings, especially for carbohydrates and sweets, as their brain chemistry shifts. The signals that once told you “I’m full” become muted, while hunger signals amplify. 

These changes help explain why your usual habits may not be giving you the same results. It’s not about discipline. Your metabolism simply works differently during this stage, and that’s exactly why adjusting your approach can make such a meaningful difference.

Understanding GLP-1 Weight Loss Medications

Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized obesity treatment, but their benefits extend far beyond simple appetite suppression. These medications include semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®). They mimic a natural gut hormone that regulates multiple metabolic processes simultaneously. 

In your brain: GLP-1 receptors in the hypothalamus reduce appetite and quiet what patients call “food noise”. This is the constant mental chatter about eating, the persistent thoughts about your next meal, the obsessive planning around food. This isn’t about willpower. It’s about resetting the neural circuits driving hunger. Many women describe this as finally having mental space for other thoughts, no longer consumed by food-related decisions. 

In your gut: These medications slow gastric emptying, helping you feel full faster and stay satisfied longer after meals. This physiological fullness differs dramatically from the constant hunger many perimenopausal women experience. You can eat smaller portions without feeling deprived because the signal of satiety arrives sooner and lasts longer. 

In your pancreas: GLP-1s improve insulin secretion and reduce glucagon release, stabilizing blood sugar levels. This helps address the insulin resistance that can develop during the menopause transition, which may break the cycle of cravings and energy crashes. Stable blood sugar can support stable energy, stable mood, and freedom from the 3 PM crash many women experience that often drives snacking.  

Clinical trials demonstrate that GLP-1 weight loss medications, when combined with lifestyle modifications, can produce 15-20% total body weight loss over 52 weeks. At Ivím Health, our peer-reviewed research on 1,131 patients showed even stronger results: an average of 45.9 pounds lost (19.5% total body weight loss) at 52 weeks, with 99% of patients losing at least 5% of their body weight. This consistency across nearly all patients suggests that when properly dosed and supported, these medications can address fundamental biological barriers to weight loss.

Hormone Replacement Therapy’s Metabolic Benefits

If you’re exploring hormone replacement therapy during perimenopause, you might already know it can help with hot flashes and sleep issues. But  many women don’t realize that estrogen’s influence extends far beyond these common symptoms.  

It actually plays a meaningful role in how your body manages metabolism and weight, which is why hormone balance can be such an important piece of the puzzle when you’re working on weight management during this phase of life. 

HRT Can Restore Insulin Sensitivity: Estrogen replacement directly improves how your cells respond to insulin, addressing the root cause of menopause-related insulin resistance. This effect helps stabilize blood sugar and reduce fat storage signals. When insulin sensitivity improves, your body can use glucose for energy rather than storing it as fat. 

HRT Supports Muscle Mass Preservation: Studies show that women on hormone replacement therapy may be able to maintain significantly more lean body mass during and after menopause compared to those without hormone therapy. One clinical trial found that early menopausal women using transdermal estrogen showed markedly greater gains in muscle strength compared to placebo. Preserving muscle becomes increasingly important as you age, not just for metabolic rate but for functional independence and bone health.

HRT Supports Reduced Visceral Fat Accumulation: Estrogen therapy helps maintain the subcutaneous fat distribution pattern of younger women, reducing dangerous visceral fat deposits around organs. This may help address the frustrating belly fat that can develop during menopause weight gain even when overall weight stays stable. The shift from hip and thigh fat to abdominal fat isn’t just about appearance. Visceral fat produces inflammatory markers that increase cardiovascular disease risk. 

HRT May Improve Sleep Quality: One of the ways hormone replacement therapy can help is by addressing sleep disruptors like night sweats and hot flashes. When you’re getting better rest, it becomes easier to manage hunger signals, maintain energy for activity, and support healthy sleep hygiene habits. Quality sleep matters for weight management because poor sleep can affect stress hormones and increase cravings, making consistent rest an important foundation during perimenopause.

The Synergistic Effect: Why Combination Therapy May Offer Enhanced Results

One of the most interesting developments in perimenopause weight management is how hormone replacement therapy and GLP-1 medications may work together. Preliminary research suggests that postmenopausal women using both approaches together tend to see more favorable outcomes than those using GLP-1 medications alone.

This pattern appears consistently across different timepoints, which has led researchers to explore whether the absence of adequate hormone levels might influence how effectively the body responds to weight loss medications during this life stage. Depending on your individual health history, hormone optimization may play a meaningful role in supporting your overall results.

Why the Combination Works Better

Hormone replacement therapy can help address hormonal deficits while GLP-1 weight loss medications target appetite and metabolism. Each fills gaps the other cannot address alone. Think of it as addressing both the “why” and the “how” of perimenopause weight gain. 

HRT Addresses: Estrogen-driven fat redistribution, muscle loss prevention, sleep disruption, hot flashes and night sweats 

GLP-1 Addresses: Appetite dysregulation, insulin resistance, blood sugar instability, inflammation reduction 

Combined Benefit: Targets both hormonal AND behavioral factors, which can help preserve lean mass while losing fat and support better energy for lifestyle changes, leading to comprehensive quality of life improvement 

Rather than competing approaches, hormone optimization therapy and GLP-1 therapy can work through distinct physiological pathways that reinforce each other. The result is sustainable perimenopause weight loss that addresses the metabolic foundation of midlife weight gain. You’re not forcing your body to fight against its biology. You’re restoring the hormonal environment that supports healthy weight maintenance.

The Ivím Health Advantage: Individualized GLP-1 Dosing

When it comes to GLP-1 medications, there’s no universal ‘perfect dose’ that works the same for everyone. This is especially true during perimenopause, when shifting hormone levels can influence how your body responds to treatment. What’s effective for one woman might need adjustment for another. 

Ivím Health developed GLP-1 Individualized Dosing (GLP-1 ID), an individualized protocol that adjusts your medication week-by-week based on how your body is responding, any side effects you’re experiencing, and the progress you’re making. Rather than following a rigid escalation schedule, this approach tailors the treatment to you.

What Makes the Ivím Health Model Different

Ivim Health’s GLP-1 ID program includes several key components working together: 

• Medical oversight from board-certified obesity medicine physicians who understand the complexities of weight management during perimenopause 

• Flexible provider access for timely dose adjustments and side effect management when you need it 

• Functional health coaching to support nutrition, lifestyle optimization, and sustainable habits 

• Community connection where you can share experiences with others on similar journeys 

• Progress tracking tools through the Ivím Health app to monitor your results and identify patterns 

This integrated approach combines clinical expertise with personalized support, something that’s particularly valuable when navigating the metabolic changes of perimenopause. 

Ivim Health focuses on making GLP-1 treatment both accessible and individualized for women navigating midlife weight management.

Your Personalized Treatment Plan

Every woman’s journey with combination therapy is unique. Your Ivím Health provider will create a customized plan based on your medical history, symptoms, and goals. Throughout treatment, you’ll have ongoing access to your care team to adjust medications, address side effects, and optimize your outcomes. 

Clinical studies show that combining hormone replacement therapy with GLP-1 medications may produce superior results, but individual experiences vary based on numerous factors. Your provider will help you set realistic expectations and track meaningful progress markers specific to your situation.

Getting Started: Your Next Steps

If you’re struggling with perimenopause weight gain or menopause weight gain despite your best efforts, combination hormone replacement therapy and GLP-1 weight loss therapy may offer the metabolic reset you need. This isn’t about willpower, it’s about addressing hormonal root causes with science-backed treatment.

Step 1: Take our 3-minute health assessment at ivimhealth.com to determine eligibility for combination therapy. Our online questionnaire evaluates your medical history, current symptoms, and weight management goals. 

Step 2: Schedule a complimentary consultation with one of Ivim Health’s experienced providers. During this telehealth visit, you’ll discuss your unique situation, review treatment options, and develop a personalized plan. 

Step 3: Begin your treatment with comprehensive support. If you’re a candidate, you’ll receive prescriptions, injection training, ongoing provider access, and the full resources of our care team. 

Treatment is accessible through HSA/FSA accounts, and our team provides prior authorization support for insurance coverage.

The Bottom Line

Perimenopause and menopause weight gain stem from hormonal changes that can make traditional weight loss approaches feel like an uphill battle. By combining hormone replacement therapy with GLP-1 medications, you’re addressing both the hormonal shifts and metabolic changes that drive weight gain during this transition. 

With Ivim Health’s individualized approach, comprehensive physician oversight, and personalized support, you gain more than a prescription; you gain a partner in navigating this challenging phase of life. Ready to explore whether hormone replacement therapy and GLP-1 combination therapy is right for you? Take our quick assessment to get started with a complimentary consultation.

Medically reviewed by Emily Bigby, MD, Physician at Ivím Health 

Medical Disclaimer:  

This content is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider before starting any new medication or treatment program. Individual results may vary. GLP-1 medications and hormone replacement therapy require prescriptions from licensed healthcare providers. Consult with a qualified physician to determine if these treatments are appropriate for your specific situation. For complete safety information about GLP-1 medications, visit our safety page. 

Tirzepatide and semaglutide are prescription medications that require medical supervision. Compounded medications have not been approved by the FDA for safety, effectiveness, or quality and should only be used when FDA-approved medications are unavailable. Brand names mentioned are for informational purposes only. Ivim Health is not affiliated with any pharmaceutical manufacturers.

Sources: 

Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric. 2012;15(5):419-429. https://doi.org/10.3109/13697137.2012.707385 

Santosa, S., & Jensen, M. D. (2013). Adipocyte Fatty Acid Storage Factors Enhance Subcutaneous Fat Storage in Postmenopausal Women. Diabetes, 62(3), 775-782. https://pubmed.ncbi.nlm.nih.gov/23209188/ 

Hurtado, M. D., Tama, E., Fansa, S., Ghusn, W., Anazco, D., Acosta, A., Faubion, S. S., & Shufelt, C. L. (2024). Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause, 31(4), 266-274. https://doi.org/10.1097/GME.0000000000002310 

Chopra, Sakshi, et al. “Weight Management Module for Perimenopausal Women: A Practical Guide for Gynecologists.” Journal of Mid-Life Health, vol. 10, no. 4, Oct.-Dec. 2019, pp. 165-72, doi:10.4103/jmh.JMH_155_19. https://pmc.ncbi.nlm.nih.gov/articles/PMC6947726/. 

De Paoli, Monica, et al. “The Role of Estrogen in Insulin Resistance: A Review of Clinical and Preclinical Data.” American Journal of Pathology, vol. 191, no. 9, Sept. 2021, pp. 1490-98, https://doi.org/10.1016/j.ajpath.2021.05.011. 

St-Onge MP, Gallagher D. Body composition changes with aging: the cause or the result of alterations in metabolic rate and macronutrient oxidation? Nutrition. 2010;26(2):152-155. https://doi.org/10.1016/j.nut.2009.07.004 

Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32(6):949-958. https://doi.org/10.1038/ijo.2008.25 

Sowers, M. F., Wildman, R. P., Mancuso, P., Eyvazzadeh, A. D., Karvonen-Gutierrez, C. A., Rillamas-Sun, E., & Jannausch, M. L. (2008). Change in adipocytokines and ghrelin with menopause. Maturitas, 59(2), 149-157. https://doi.org/10.1016/j.maturitas.2007.12.006 

Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. https://doi.org/10.1111/dom.14280 

van Can, J., et al. “Effects of the Once-Daily GLP-1 Analog Liraglutide on Gastric Emptying, Glycemic Parameters, Appetite and Energy Metabolism in Obese, Non-Diabetic Adults.” International Journal of Obesity, vol. 38, no. 6, June 2014, pp. 784-93. https://pubmed.ncbi.nlm.nih.gov/23999198/ 

Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. https://doi.org/10.1016/j.molmet.2019.09.010 

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183 

Duncan, Jessica, et al. “Individualized Virtual Integrative Medicine (IVIM): A Clinical Model for Enhanced GLP-1 Therapeutic Outcomes.” Obesity Pillars, vol. 15, Sept. 2025, 100188, https://www.sciencedirect.com/science/article/pii/S2667368125000324. 

Mauvais-Jarvis, Franck, et al. “Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications.” Endocrine Reviews, vol. 38, no. 3, June 2017, pp. 173-88, https://doi.org/10.1210/er.2016-1146. 

Ronkainen PHA, Kovanen V, Alén M, et al. Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: a study with monozygotic twin pairs. J Appl Physiol. 2009;107(1):25-33. https://doi.org/10.1152/japplphysiol.91518.2008 

Dam, Tine Vrist, et al. “Transdermal Estrogen Therapy Improves Gains in Skeletal Muscle Mass After 12 Weeks of Resistance Training in Early Postmenopausal Women.” Frontiers in Physiology, vol. 11, 2021, article 596130, https://doi.org/10.3389/fphys.2020.596130. 

Steiner, Benjamin M., and Daniel C. Berry. “The Regulation of Adipose Tissue Health by Estrogens.” Frontiers in Endocrinology, vol. 13, 25 May 2022, www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.889923/full. 

Cintron D, Lipford M, Larrea-Mantilla L, et al. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. Endocrine. 2017;55(3):702-711. https://doi.org/10.1007/s12020-016-1072-9 

Hurtado, Maria D., et al. “Weight Loss Response to Semaglutide in Postmenopausal Women With and Without Hormone Therapy Use.” Menopause, vol. 31, no. 4, Apr. 2024, pp. 266-74, doi:10.1097/GME.0000000000002310. https://pubmed.ncbi.nlm.nih.gov/38446869/.